A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.
Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.
shanghai microport endovascular medtech(group)co.,ltd. net profit in the first half of the year increased by more than 44%. Can going overseas alleviate the impact of Castor price reduction?
①Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. accelerated its "going abroad" strategy, and its overseas revenue in the first half of the year increased by 67.04% year-on-year, accounting for 8.84% of the total revenue increase. ②A reporter from "Science and Technology Innovation Board Daily" asked personnel from Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. whether they would correspondingly reduce the selling price to dealers in response to the significant price reduction of the Castor bracket terminal. The other party refused to disclose more information, citing "inconvenience to reply".
Innovative drugs also pays dividends! Shanghai Allist Pharmaceuticals Co., Ltd. earns 0.66 billion in the first half of the year and pays a generous dividend of 0.113 billion | Jiangu Intelligence Research.
The advantages of medical insurance are highlighted. In the first half of the year, the sales of Shanghai Allist Pharmaceuticals Co., Ltd.'s vemurafenib reached 1.555 billion. Sales expenses decreased quarter-on-quarter in the second quarter, with cash on hand exceeding 2.6 billion.
Continued high investment in R&D and advancing market expansion, Autobio Diagnostics' first-half revenue and net profit both doubled, according to the announcement.
1. Autobio Diagnostics achieved growth in both H1 revenue and net profit, with the proportion of research and development expenses increasing continuously in total revenue. 2. The proportion of the company's reagent business revenue did not increase as expected. 3. The company plans to add actual production support for subdivided fields in the project of expanding the production capacity of in vitro diagnostic products.
Sell for 0.12 million by agents when it was made for 0.05 million? The National Healthcare Security Administration asks four questions of Shanghai MicroPort Endovascular Medtech (Group) Co., Ltd. The latest response has arrived.
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. received an inquiry letter from the National Medical Insurance Bureau due to the suspected overpricing of Castor stents. Company employees revealed that internal meetings are being held to address this issue. In order to cope with competition pressure in the domestic market, including pressure from early response to centralized procurement, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. is accelerating its layout in overseas markets.
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.